Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
Provider: MacroRisk Analytics/EconomicInvestor
Provider: ValuEngine, Inc.
Provider: S&P Capital IQ Quantitative Report

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Catalyst Pharmaceutical Partners Inc Announces Offering Of Shares - Form 8-K

Thursday, 5 Sep 2013 09:16am EDT 

Catalyst Pharmaceutical Partners Inc reported in its Form 8-K that it has entered into Subscription Agreements (collectively, the Subscription Agreement) with investors who agreed to purchase an aggregate of 8,800,000 shares (the Shares) of the Company’s common stock, par value $0.001 per share for a purchase price of $1.72 per Share, or an aggregate of $15.1 million in gross proceeds. Roth Capital Partners, LLC (“Roth”) acted as Placement Agent for the offering of the Shares (the Offering). Further, Aegis Capital Corporation, Maxim Group LLC and H.C. Wainright & Co. acted as financial advisors in connection with the offering. The closing of the Offering is expected to take place on September 10, 2013, subject to the satisfaction of customary closing conditions.